-
Mashup Score: 0
The company presented on the preliminary activity of RMC-4630 combined with Cotellic and said it is studying the SHP2 inhibitor alongside an AstraZeneca drug.
Source: Precision Oncology NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3NCI-MATCH Data Shows Value of Platform Trials for Patients With Rare Genomically Driven Cancers - 5 year(s) ago
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TurnaRay: NCI-MATCH Data Shows Value of Platform Trials for Patients With Rare Genomically Driven Cancers https://t.co/wUenQPnKG0
-
-
Mashup Score: 0COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials - 5 year(s) ago
The pandemic has underscored the importance of “bringing the trial to the patient,” a concept that is likely to persist, particularly in precision oncology.
Source: Precision Oncology NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials https://t.co/11Zo0aXpNY
-
-
Mashup Score: 1MSK Clonal Hematopoiesis Clinic Aims to Drive New Strategies for Cancer Risk Assessment, Prevention - 5 year(s) ago
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
Source: Precision Oncology NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MSK Clonal Hematopoiesis Clinic Aims to Drive New Strategies for Cancer Risk Assessment, Prevention https://t.co/iJtzpXaYgY
-
-
Mashup Score: 0Patients With BRAF-Mutated Bile Duct Cancer See Benefit from Targeted Treatment Combination - 5 year(s) ago
The first prospective study of BRAF-mutated cholangiocarcinoma showed a 51 percent response rate among patients treated with Novartis’ Tafinlar and Mekinist.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
always proud of the man @VivekSubbiah when he gets quoted, which now happens almost about...ummmm.....hourly??? https://t.co/nOrX0kP5Mf
-
-
Mashup Score: 1
Over the last six months the agency approved 21 cancer treatments for molecularly defined indications compared to 12 during the same period last year and 20 during all of 2019.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA Approves Record Number of Precision Oncology Drugs in H1 2020 https://t.co/tM96tc6Ums
-
-
Mashup Score: 1Precision Oncology Programs Adapting to Ensure Patient Safety, Care During Public Health Crisis - 5 year(s) ago
Health systems’ molecular testing labs haven’t had to cut back on genomic profiling for cancer patients yet but may need to accommodate COVID-19 testing if needed.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Precision Oncology Programs Adapting to Ensure Patient Safety, Care During Public Health Crisis https://t.co/JTqvL6ibFD
-
-
Mashup Score: 4
From changes in trial enrollment to increased flexibility, clinical trials in precision oncology and other fields are feeling the brunt of the ongoing COVID-19 pandemic.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Great overview of impact of COVID-19 on precision oncology trials by @andyandy_tk #COVID19ClinicalTrials #COVID19 https://t.co/HNBjRFzJsi
-
-
Mashup Score: 18
Over the last six months the agency approved 21 cancer treatments for molecularly defined indications compared to 12 during the same period last year and 20 during all of 2019.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA Approves Record Number of Precision Oncology Drugs in H1 2020 https://t.co/ROdfWup7FT
-
-
Mashup Score: 0Aprea Therapeutics Expanding Eprenetapopt Trial in TP53-Mutant Acute Myeloid Leukemia - 5 year(s) ago
The drug, designed to reactivate p53, will be evaluated in combination with chemotherapy and Venclexta as a frontline treatment for patients with TP53-mutant AML.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Aprea Therapeutics Expanding Eprenetapopt Trial in TP53-Mutant Acute Myeloid Leukemia https://t.co/4KGijxKtyd
-
Revolution Medicines Expands Development of SHP2 Inhibitor in KRAS-Mutated Cancers https://t.co/NUe60GbBVR